# US 10,501,543 B2 · IL15/IL15Rα heterodimeric Fc-fusion proteins

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,501,543 B2
- Document ID: US10501543B2
- Status: Granted
- Kind: B2
- Application number: 15/785,401
- Filed: 2017-10-16
- Published: 2018-05-03
- Granted: 2019-12-10
- Earliest claimed: 2016-10-14
- Assignees: Xencor, Inc.
- Applicants: Xencor, Inc.
- Inventors: Matthew Bernett; Rumana Rashid; John Desjarlais; Rajat Varma; Christine Bonzon
- Web page: https://patentgrep.com/patent/US10501543B2

## CPC

- C07K 16/2818: {against CD28 or CD152}
- A61P 35/00: Antineoplastic agents
- C07K 14/5443: {IL-15}
- C07K 14/7155: {for interleukins [IL]}
- C12N 15/63: Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/31: multispecific
- C07K 2317/35: Valency
- C07K 2317/524: CH2 domain
- C07K 2317/526: CH3 domain
- C07K 2317/53: Hinge
- C07K 2317/55: Fab or Fab'
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/74: Inducing cell proliferation
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K 2319/32: fusions with soluble part of a cell surface receptor, "decoy receptors"
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention is directed to novel IL15/IL15Rα heterodimeric Fc fusion proteins.

## Claims

### Claim 1

A heterodimeric protein comprising:
a) a first monomer comprising SEQ ID NO:1014; and
b) a second monomer comprising SEQ ID NO:1017.

### Claim 2

A nucleic acid composition comprising:
a) a first nucleic acid sequence encoding SEQ ID NO:1014; and
b) a second nucleic acid sequence encoding SEQ ID NO:1017.

### Claim 3

An expression vector composition comprising:
a) a first expression vector comprising a first nucleic acid sequence encoding SEQ ID NO:1014; and
b) a second expression vector comprising a second nucleic acid sequence encoding SEQ ID NO:1017.

### Claim 4

An expression vector composition comprising an expression vector comprising a first nucleic acid sequence encoding SEQ ID NO:1014; and a second nucleic acid sequence encoding SEQ ID NO:1017.

### Claim 5 (depends on 3, 4)

A host cell comprising the expression vector composition of claim 3 or 4.

### Claim 6 (depends on 5)

A method of producing a heterodimeric protein comprising culturing the host cell of claim 5 under suitable conditions wherein said heterodimeric protein is expressed, and recovering said protein.